Beam Therapeutics Stock Alpha and Beta Analysis

BEAM Stock  USD 24.23  0.83  3.31%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Beam Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Beam Therapeutics over a specified time horizon. Remember, high Beam Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Beam Therapeutics' market risk premium analysis include:
Beta
1.08
Alpha
0.0637
Risk
4.51
Sharpe Ratio
(0.04)
Expected Return
(0.19)
Please note that although Beam Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Beam Therapeutics did 0.06  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Beam Therapeutics stock's relative risk over its benchmark. Beam Therapeutics has a beta of 1.08  . Beam Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Beam Therapeutics is expected to follow. At this time, Beam Therapeutics' Price Book Value Ratio is very stable compared to the past year. As of the 16th of March 2025, Price Fair Value is likely to grow to 2.92, while Tangible Book Value Per Share is likely to drop 5.57.

Enterprise Value

3.19 Billion

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Beam Therapeutics Backtesting, Beam Therapeutics Valuation, Beam Therapeutics Correlation, Beam Therapeutics Hype Analysis, Beam Therapeutics Volatility, Beam Therapeutics History and analyze Beam Therapeutics Performance.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

Beam Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Beam Therapeutics market risk premium is the additional return an investor will receive from holding Beam Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Beam Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Beam Therapeutics' performance over market.
α0.06   β1.08

Beam Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Beam Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Beam Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Beam Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Beam Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Beam Therapeutics shares will generate the highest return on investment. By understating and applying Beam Therapeutics stock market price indicators, traders can identify Beam Therapeutics position entry and exit signals to maximize returns.

Beam Therapeutics Return and Market Media

The median price of Beam Therapeutics for the period between Mon, Dec 16, 2024 and Sun, Mar 16, 2025 is 26.8 with a coefficient of variation of 8.48. The daily time series for the period is distributed with a sample standard deviation of 2.3, arithmetic mean of 27.18, and mean deviation of 1.72. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Insider Trading
12/19/2024
2
Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3
12/20/2024
3
Is it a Good Idea to Invest in Beam Therapeutics Stock Now
01/24/2025
4
Disposition of 6287 shares by Bethany Cavanagh of Beam Therapeutics at 35.0 subject to Rule 16b-3
02/18/2025
5
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
02/25/2025
6
Beam Therapeutics Full Year 2024 Earnings Beats Expectations
02/26/2025
7
Equities Research Analysts Updated EPS Estimates for February 27th
02/27/2025
8
Is Beam Therapeutics Inc. the Best Emerging Technology Stock to Buy Now
03/10/2025
9
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
03/11/2025
10
Beam Therapeutics price target raised by 8 at Citi, heres why BEAM
03/13/2025

About Beam Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Beam or other stocks. Alpha measures the amount that position in Beam Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2024 2025 (projected)
Dividend Yield0.01190.0106
Price To Sales Ratio32.1430.53

Beam Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Beam Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Beam Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Beam Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Beam Therapeutics. Please utilize our Beneish M Score to check the likelihood of Beam Therapeutics' management manipulating its earnings.
27th of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Beam Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:
Beam Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Beam Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Beam Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...